LLY — ELI LILLY AND COMPANY (Healthcare >> Drug Manufacturers - General)
LLY FAQ
What is LLY's P/E ratio?
ELI LILLY AND COMPANY (LLY) currently trades at a P/E ratio of 37.54.
What is LLY's ROE?
ELI LILLY AND COMPANY reports a Return on Equity (ROE) of 81.01%.
What is LLY's dividend yield?
ELI LILLY AND COMPANY offers a dividend yield of 0.58%.
What is LLY's Deepscope Quality Score?
Deepscope rates LLY's overall financial quality at 92 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LLY?
Deepscope's AI Timing Score for LLY is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LLY belong to?
ELI LILLY AND COMPANY is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange.
|
USD 1,078.78
Price
14.63
(1.37%)
Day Change
|
|
|---|
LLY Chất lượng tổng thể của cố phiếu Xuất sắc ( Chất lượng = 92) và Thời điểm mua ...(Sign In to See)...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROA quá thấp so với ROE
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Khá , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Rất tốt , ...
| Yếu tố Chất lượng |
|
61% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.08 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
1112
|
| Magic Formula Rank by ROE |
1112
|
| Magic Formula Rank by ROIC |
1213
|
| Price | 1,078.78 |
| PBV / Sector |
30.42 / 2.77
|
| Earning Per Share | 28.73 |
| PE / Sector |
37.54 / 23.60
|
| PEG or PE/Growth / Sector |
0.60 / 0.07
GOOD
|
| Average 1M Daily Value |
2,542.12 M
GREAT
|
| Average 1W Daily Value |
2,991.06 M
GREAT
|
| Yếu tố Kỹ thuật |
|
71% |
| Sức khỏe tài chính |
|
52% |
| Khả năng kiếm lợi nhuận |
|
81% |
| Lợi tức cho nhà đầu tư |
|
12% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-04 09:24:28 |
| Symbol | LLY |
| Name | ELI LILLY AND COMPANY |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 891.74 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 948,946.60 / 232,396.15 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Lilly Corporate Center, Indianapolis, IN, United States, 46285
Phone: 317 276 2000
Website: https://www.lilly.com
Employees: 50,000
Description: Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
Google